Shanghai INT Medical Instruments Co Graham Number
The Graham Number of Shanghai INT Medical Instruments Co (1501.HK) as of Oct 11, 2026 is 19.06 CNY. In the previous year, Graham Number was 15.46 CNY — a change of 23.25% (higher).
Get this data via API
Financial Data API
Graham Number
19.06CNY
YoY
23.25%
Last updated:
Graham Number of Shanghai INT Medical Instruments Co is 2025 19.06 CNY. Graham Number of Shanghai INT Medical Instruments Co was 2024 15.46 CNY. It decreases by 23.25% higher compared to the previous year.
The Shanghai INT Medical Instruments Co Graham Number history
3 Years
10 Years
25 Years
Max
Graham Number
Date
Graham Number
Jan 1, 2018
4.28 CNY
Jan 1, 2019
9.84 CNY
Jan 1, 2020
10.08 CNY
Jan 1, 2021
13.11 CNY
Jan 1, 2022
12.97 CNY
Jan 1, 2023
13.63 CNY
Jan 1, 2024
15.46 CNY
Jan 1, 2025
19.06 CNY
| YEAR | Graham Number | YoY |
|---|---|---|
| 19.06CNY | +23.25% | |
| 15.46CNY | +13.43% | |
| 13.63CNY | +5.14% | |
| 12.97CNY | -1.12% | |
| 13.11CNY | +30.05% | |
| 10.08CNY | +2.49% | |
| 9.84CNY | +130.07% | |
| 4.28CNY | +83.43% | |
| 2.33CNY | +22.71% | |
| 1.90CNY | — |
Access this data via the Eulerpool API
Shanghai INT Medical Instruments Co Stock analysis
What does Shanghai INT Medical Instruments Co do? Shanghai INT Medical Instruments Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Shanghai INT Medical Instruments Co stock
Graham Number of Shanghai INT Medical Instruments Co is 19.06 CNY in 2025.
On Eulerpool you can find the complete historical development of Graham Number Shanghai INT Medical Instruments Co since 2006 – with annual values, charts, and detailed analysis.
The Graham Number estimates the maximum fair price for a stock based on EPS and book value per share, following Benjamin Graham's value investing principles.
Access this data via the Eulerpool API
Quality — Shanghai INT Medical Instruments Co
All Key Metrics — Shanghai INT Medical Instruments Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth